固形腫瘍微小環境におけるマスト細胞:複数の役割と標的治療の可能性
Chenglu Lu1, Huiting Zhang2, Ujjal K Bhawal3,4
1Department of Pathology, Hebei Key Laboratory of Molecular Oncology, The Cancer Institute, Tangshan People's Hospital, Tangshan, 063001, China.
Oncology research
|December 22, 2025
まとめ
腫瘍微小環境(TME)内のマスト細胞(MC)は、がんの増殖を促進または阻害するという複雑な役割を持っています。MCを理解することは、がん治療のための新しい治療戦略を提示します。
科学分野:
- 腫瘍学
- 免疫学
- 細胞生物学
背景:
- 腫瘍微小環境(TME)は、腫瘍の進行に影響を与える複雑な生態系である。
- マスト細胞(MC)はTME内の主要な免疫細胞であり、その役割については議論がある。
- MCは、文脈に応じて腫瘍の増殖を促進または阻害する二重の調節機能を示す。
研究 の 目的:
- 腫瘍微小環境におけるマスト細胞に関する現在の理解を体系的にレビューする。
- 腫瘍の種類、病理学的状態、種を超えたMCの特徴と機能の違いを強調する。
- がん治療における新たな治療標的としてのMCを探求する。
主な方法:
- TMEにおけるマスト細胞の研究に関する包括的な文献レビュー。
- MCマーカー、活性化メカニズム、生物学的機能の分析。
- 細胞間相互作用とMCの治療的調節の検討。
主要な成果:
- マスト細胞は腫瘍の進行において文脈依存的な役割(腫瘍促進性または抗腫瘍性)を示す。
- がんの種類や種によってMCの挙動に大きなばらつきが存在する。
- MCの理解の進展は、標的治療戦略への道を開く。
結論:
- マスト細胞はTMEの重要かつ多面的な構成要素である。
- 特定のMCサブセットを標的とすることは、がん治療の有望な道筋となる。
- MCに関するさらなる研究は、腫瘍免疫学と治療の将来の方向性を形作るだろう。
関連する概念動画
The Tumor Microenvironment
7.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.6K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Mesenchymal Stem Cells
5.5K
Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their...
5.5K
Drugs that Stabilize Microtubules
2.6K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.6K
Mitogens and the Cell Cycle
7.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K
Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K


